BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Non-GAAP Adjusted Gross Margin by Quarter
Non-GAAP Adjusted Gross Margin (% of Global Product Sales, FY23–FY25) (%)
BeOne Medicines Non-GAAP Adjusted Gross Margin: 90.7% in Q4 2025, up 3.3 pts from a year earlier. That is the highest of the 9 quarters on record here.
Where the Q4 2025 figure comes from
“On an adjusted basis, which does not include depreciation and amortization, gross margin as a percentage of global product sales increased to 90.7% and 87.8% for the fourth quarter and full year of 2025, compared to 87.4% and 85.5%”
Source: Form 8-K (filed 2026-02-26) ↗
Reported in Form 8-K EX-99.1 Earnings Releases & Form 10-K MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP Adjusted Gross Margin (% of Global Product Sales, FY23–FY25) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2025 | Dec 31, 2025 | 90.7% | +3.3 pts | Form 8-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 86.3% | +1.4 pts | Form 8-K (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 88.1% | +2.7 pts | Form 8-K (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 85.5% | +1.8 pts | Form 8-K (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 87.4% | +3.7 pts | Form 8-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 84.9% | – | Form 8-K (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 85.4% | – | Form 8-K (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 83.7% | – | Form 8-K (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 83.7% | – | Form 8-K (filed 2025-02-27) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Non-GAAP Adjusted Gross Margin (%), quarterly Q4 2023–Q4 2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/adj-gm-pct
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.